Theravance (THRX) Anoro COPD Studies Gives Baird Increased Confidence

Baird analyst Brian Skorney has increased confidence in the potential of Theravance Inc. (NASDAQ: THRX) Anoro following randomized COPD studies. He reiterated an Outperform rating and price target of $44.00.

Skorney commented, "With positive results across three studies against either dose of fluticasone propionate/salmeterol, Anoro continues to build its safety and efficacy profile against key competitors. Aside from the advantage Anoro has with QD dosing, we believe the demonstrated superior efficacy to Advair adds further differentiation in the COPD market."

For an analyst ratings summary and ratings history on Theravance Inc. click here. For more ratings news on Theravance Inc. click here.

Shares of Theravance Inc. closed at $33.94 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'